September 14, 2017
Reposting this article to relate to my earlier piece:
Are drug companies grooming new customers in the womb?
Patrick D HahnIn March, drugmaker GlaxoSmithKline agreed to pay $6.2 million to settle a class-action lawsuit on behalf of children born with congenital defects whose mothers used GSK’s blockbuster drug Paxil while pregnant. Just days before the agreement was announced, an updated analysis of the Quebec Pregnancy Cohort in BMJ Open, an online journal, showed that for the period 1998-2009, antidepressant use during pregnancy in the study population more than doubled, and the rate of major congenital malformations increased as well, by more than 50 percent. The rate of maternal depression in the study population also went up — odd, given that these drugs are supposed to be relieving depression.